Prostate cancer epidemiology and demographics
Jump to navigation
Jump to search
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2] Muhammad Saad, M.B.B.S.[3] Syed Musadiq Ali M.B.B.S.[4] Kavya Keerthi Vadlamudi, M.B.B.S.[5]
|
Prostate cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Prostate cancer epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Prostate cancer epidemiology and demographics |
|
Risk calculators and risk factors for Prostate cancer epidemiology and demographics |
Overview
In 2022, there were 1,466,680 new cases of prostate cancer in men worldwide. In 2020, there are expected to be approximately 191,930 new prostate cancer diagnoses and approximately 33,330 prostate cancer deaths. The number of deaths was 19.0 per 100,000 men per year. These rates are age-adjusted and based on 2013-2018 cases and deaths. Approximately 12.1 percent of men will be diagnosed with prostate cancer at some point during their lifetime, based on 2013-2017 data. In 2017, an estimated 3,170,339 men were living with prostate cancer in the United States.
Epidemiology and Demographics
Prevalence
- In 2021, there were an estimated 3,399,229 men living with prostate cancer in the United States.[1]
- In 2017, there were an estimated 3,170,339 men living with prostate cancer in the United States.[2]
- Rates of prostate cancer vary widely across the world. Although the rates vary widely between countries, it is least common in South and East Asia, more common in Europe, and most common in the United States.[3]
Incidence
- In 2022, there were 1,466,680 new cases of prostate cancer in men worldwide.[4]
- In 2020, there are expected to be approximately 191,930 new prostate cancer diagnoses and approximately 33,330 prostate cancer deaths[5].
- Prostate cancer is second only to non-melanoma skin cancer and lung cancer as the leading cause of cancer and cancer death, respectively, in United States men.
- In 2022, there were an estimated 1,466,680 new cases of prostate cancer and 396,792 prostate cancer deaths, making it the second most commonly diagnosed cancer in men and cancer death[6][4].
Age
- The incidence of prostate cancer increases with age; the median age at diagnosis is 67 years.[1]
- Shown below is an image depicting the incidence of prostate cancer by age and race in the United States between 1975 and 2015.[7]
Race
- The annual incidence rate of prostate cancer is 173.0 cases per 100,000 Black men vs 97.1 per 100,000 White men.[8][9]
- It usually affects individuals of the African American race. Asian, Hispanic and White individuals are less likely to develop prostate cancer.
- Shown below is a table depicting the age-adjusted rate of prostate cancer by race in 2015 in the United States.[7]
| All Races | White | Black | Asian/Pacific Islander | Hispanic | |
| Age-adjusted prevalence | 19.5 per 100,000 | 18.2 per 100,000 | 39.9 per 100,000 | 8.8 per 100,000 | 16.2 per 100,000 |
- Shown below is an image depicting the incidence of prostate cancer by race in the United States between 1975 and 2015.[10]
Genetic Predisposition:
- Prostate cancer is highly hereditable
- More than 50% of prostate cancer risk is attributable to genetic factors, as shown by studies performed in Northern Europe.[11]
References
- ↑ 1.0 1.1 Cancer of the Prostate - Cancer Stat Facts. (n.d.). SEER. Retrieved February 11, 2026, from https://seer.cancer.gov/statfacts/html/prost.html
- ↑ "Prostate Cancer - Cancer Stat Facts".
- ↑ "IARC Worldwide Cancer Incidence Statistics—Prostate". JNCI Cancer Spectrum. Oxford University Press. December 19, 2001. Retrieved on 2007-04-05 through the Internet Archive
- ↑ 4.0 4.1 Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024). "Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries". CA Cancer J Clin. 74 (3): 229–263. doi:10.3322/caac.21834. PMID 38572751 Check
|pmid=value (help). - ↑ Siegel RL, Miller KD, Jemal A (January 2018). "Cancer statistics, 2018". CA Cancer J Clin. 68 (1): 7–30. doi:10.3322/caac.21442. PMID 29313949.
- ↑ Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, Dandona L, Fleming T, Forouzanfar MH, Hancock J, Hay RJ, Hunter-Merrill R, Huynh C, Hosgood HD, Johnson CO, Jonas JB, Khubchandani J, Kumar GA, Kutz M, Lan Q, Larson HJ, Liang X, Lim SS, Lopez AD, MacIntyre MF, Marczak L, Marquez N, Mokdad AH, Pinho C, Pourmalek F, Salomon JA, Sanabria JR, Sandar L, Sartorius B, Schwartz SM, Shackelford KA, Shibuya K, Stanaway J, Steiner C, Sun J, Takahashi K, Vollset SE, Vos T, Wagner JA, Wang H, Westerman R, Zeeb H, Zoeckler L, Abd-Allah F, Ahmed MB, Alabed S, Alam NK, Aldhahri SF, Alem G, Alemayohu MA, Ali R, Al-Raddadi R, Amare A, Amoako Y, Artaman A, Asayesh H, Atnafu N, Awasthi A, Saleem HB, Barac A, Bedi N, Bensenor I, Berhane A, Bernabé E, Betsu B, Binagwaho A, Boneya D, Campos-Nonato I, Castañeda-Orjuela C, Catalá-López F, Chiang P, Chibueze C, Chitheer A, Choi JY, Cowie B, Damtew S, das Neves J, Dey S, Dharmaratne S, Dhillon P, Ding E, Driscoll T, Ekwueme D, Endries AY, Farvid M, Farzadfar F, Fernandes J, Fischer F, G/Hiwot TT, Gebru A, Gopalani S, Hailu A, Horino M, Horita N, Husseini A, Huybrechts I, Inoue M, Islami F, Jakovljevic M, James S, Javanbakht M, Jee SH, Kasaeian A, Kedir MS, Khader YS, Khang YH, Kim D, Leigh J, Linn S, Lunevicius R, El Razek H, Malekzadeh R, Malta DC, Marcenes W, Markos D, Melaku YA, Meles KG, Mendoza W, Mengiste DT, Meretoja TJ, Miller TR, Mohammad KA, Mohammadi A, Mohammed S, Moradi-Lakeh M, Nagel G, Nand D, Le Nguyen Q, Nolte S, Ogbo FA, Oladimeji KE, Oren E, Pa M, Park EK, Pereira DM, Plass D, Qorbani M, Radfar A, Rafay A, Rahman M, Rana SM, Søreide K, Satpathy M, Sawhney M, Sepanlou SG, Shaikh MA, She J, Shiue I, Shore HR, Shrime MG, So S, Soneji S, Stathopoulou V, Stroumpoulis K, Sufiyan MB, Sykes BL, Tabarés-Seisdedos R, Tadese F, Tedla BA, Tessema GA, Thakur JS, Tran BX, Ukwaja KN, Uzochukwu B, Vlassov VV, Weiderpass E, Wubshet Terefe M, Yebyo HG, Yimam HH, Yonemoto N, Younis MZ, Yu C, Zaidi Z, Zaki M, Zenebe ZM, Murray C, Naghavi M (April 2017). "Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study". JAMA Oncol. 3 (4): 524–548. doi:10.1001/jamaoncol.2016.5688. PMID 27918777. Vancouver style error: non-Latin character (help)
- ↑ 7.0 7.1 "Browse the SEER Cancer Statistics Review 1975-2015".
- ↑ Jahn JL, Giovannucci EL, Stampfer MJ (December 2015). "The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era". Int J Cancer. 137 (12): 2795–802. doi:10.1002/ijc.29408. PMC 4485977. PMID 25557753.
- ↑ Bell KJ, Del Mar C, Wright G, Dickinson J, Glasziou P (October 2015). "Prevalence of incidental prostate cancer: A systematic review of autopsy studies". Int J Cancer. 137 (7): 1749–57. doi:10.1002/ijc.29538. PMC 4682465. PMID 25821151.
- ↑ Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.
- ↑ Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, Graff RE, Holst K, Möller S, Unger RH, McIntosh C, Nuttall E, Brandt I, Penney KL, Hartman M, Kraft P, Parmigiani G, Christensen K, Koskenvuo M, Holm NV, Heikkilä K, Pukkala E, Skytthe A, Adami HO, Kaprio J (January 2016). "Familial Risk and Heritability of Cancer Among Twins in Nordic Countries". JAMA. 315 (1): 68–76. doi:10.1001/jama.2015.17703. PMC 5498110. PMID 26746459.